Can you switch from Humira (adalimumab) to Skyrizi (risankizumab) for Crohn’s disease?
Switching is sometimes possible, but Skyrizi is not generally used for Crohn’s disease the same way Humira is. Humira (adalimumab) is a TNF inhibitor approved for Crohn’s disease, while Skyrizi (risankizumab) is an IL-23 inhibitor approved for certain other immune-mediated conditions. Because the approvals and evidence differ by disease and indication, whether Skyrizi is an option for a specific Crohn’s case depends on the exact diagnosis, prior treatments, and local prescribing guidance.
What would a doctor consider before switching biologics in Crohn’s?
A clinician typically weighs several factors:
- Disease type and location (the exact Crohn’s phenotype matters)
- What Humira was used for (and how well it controlled symptoms)
- Why Humira is being stopped (primary non-response, loss of response, side effects, or safety concerns)
- Infection risk and screening status (for example, tuberculosis and hepatitis screening)
- Whether to do a “washout” period or start the new drug promptly to avoid a gap in control
- How you’ve responded to other biologics already (switching “within class” vs “out of class”)
Your prescriber can map these factors to a safe transition plan.
Is there any situation where Skyrizi could be used for Crohn’s instead of Humira?
If Skyrizi is being discussed for Crohn’s, it would usually be because the treating team believes it fits your specific situation (for example, based on the labeled indication where you live, specialist guidance, or an off-label approach). The deciding point is whether Skyrizi is approved for Crohn’s disease in your jurisdiction and whether there’s clinical justification based on your treatment history.
What risks come with switching from Humira to a different biologic?
Switching biologics can bring practical risks that matter for Crohn’s patients:
- Loss of disease control during the transition period (symptoms can flare)
- Side effects from the new medication
- Ongoing infection risk with immune suppression
- The possibility that the new drug won’t work even if Humira stopped working for a specific reason
These risks are why timing (sometimes including how long to wait between therapies) and monitoring are individualized.
How long does it take to know if the new drug is working?
Even when switching is appropriate, Crohn’s biologics often take time to show full benefit. Your clinician will usually set expectations for early symptom improvement and longer-term response, and will decide whether to continue, adjust, or switch again based on objective measures (symptoms plus labs and sometimes endoscopy or imaging).
What should you ask your GI specialist at the next visit?
Bring up the key questions that determine whether Skyrizi is a real alternative for you:
- Is Skyrizi approved for Crohn’s disease where I live, for my specific Crohn’s type?
- Why did Humira stop working for me, and does that predict better response to another class?
- What transition plan do you recommend to avoid flare or unnecessary immune suppression?
- How will we monitor response and safety after switching?
If you want, I can help narrow it down
Tell me:
1) Your Crohn’s diagnosis details (if you know: small bowel/colon/both, fistulizing or not)
2) Why you’re switching off Humira (loss of response vs side effects)
3) Any other Crohn’s meds you’ve tried (especially other biologics)
4) Your country (approvals differ)
and I’ll explain what typically drives the decision and what options to discuss with your doctor.
Sources
1. DrugPatentWatch.com